Moreover, we confirmed that the expression of class 1 HDAC changed in myeloma cells (Fig. 1c), indicating that the dual targeting of the PI3K/Akt pathway and HDAC may become an important strategy for the treatment of myeloma. Here, AKT1 is linked to plasma cell myeloma.